Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07760792
Recruiting Observational

Risk Factors and Clinical Implications of Double-J Ureteral Stent Bacterial Colonization

NCT07760792 · tracked via the Priya Life Science Egypt tracker
Sponsor
Al-Azhar University
Phase
Observational
Started
2026-08-10
Last updated
2026-09-01

Condition(s) studied

Bacterial ColonizationDouble-J Ureteral Stents

Study summary

This prospective cohort study will evaluate the risk factors associated with bacterial colonization of Double-J ureteral stents and examine its clinical implications. Adult patients undergoing temporary ureteral stent insertion for routine urological indications will be followed until stent removal, when urine and stent cultures will be obtained. The study will assess the association between colonization and factors such as indwelling time, diabetes mellitus, chronic kidney disease, prior urinary tract infection, prior antibiotic exposure, and stent-related symptoms.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 18 years or older. * Temporary Double-J stent insertion. * Standard urological indication. * Planned stent removal during follow-up. * Ability to attend follow-up and provide specimens. * Written informed consent. Exclusion Criteria: * Active urosepsis at insertion. * Permanent or intended long-term stenting. * Concomitant nephrostomy tube or urinary diversion. * Severe immunosuppression or neutropenia. * Incomplete baseline data. * Loss to follow-up or failure to retrieve the stent. * Refusal to participate.

Primary outcome measure(s)

  • Bacterial colonization of the Double-J ureteral stent — At the time of stent removal, assessed from 2 weeks up to 52 weeks after stent insertion.
    Positive growth on stent culture at removal.

Trial sites (1)

FacilityCityRegionStatus
Department of Urology, Al-Hussein and Sayed Galal University Hospitals, Al-Azhar University Cairo Cairo Governorate Recruiting

More Al-Azhar University trials in Egypt

"Augmented Reality-Assisted Miniscrew Placement in Orthodontics: A Clinical Trial" Starting soon
Omega-3 Plus Low-Dose Aspirin in Smokers With Stage III Periodontitis Recruiting
Low-Intensity Shock Wave Therapy for Refractory Overactive Bladder in Women Starting soon
Management of Early Onset Scoliosis by Active Apex Correction Technique Recruiting
Comparative Dose-Response of Intrathecal Dexmedetomidine for Post-Spinal Shivering Starting soon

Other trials for the same condition

Risk Factors and Clinical Implications of Double-J Ureteral Stent Bacterial Colonization: A Prospective Cohort Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07760792 on ClinicalTrials.gov ↗ ← All trials in Egypt